A new tuberculosis vaccine has shown positive results in trials with mice. If this study succeeds this would be the first new tuberculosis vaccine. This could be a big help to public health as the number of death cases caused by tuberculosis is increasing.
The new tuberculosis vaccines use biobeads as a platform to present the antigens from the tuberculosis bacterium to the immune system. These are as a platform to present the antigens from the tuberculosis bacterium to the immune system. Researchers designed them to display Mycobacterium tuberculosis or Mycobacterium bovis.
Based on the researchers' observation they developed a hypothesis that these proteins could also function as antigens. Biobeads should carry mycobacterial antigens on their surface. Including many as yet undiscovered antigens which would have the potential to induce protective immunity.
According to the Science Daily, the new tuberculosis vaccine research uses these mycobacterial biobeads to vaccinate mice and tested the mice for immune responses. Evidence of cell-mediated immunity with the potential to be protective against TB was seen. Their future study goals immunization and protection as well as more efficient production and purification methods for the vaccine.
In 2015, 10.4 million got ill with tuberculosis, and 1.8 million died. This is according to the world Health Organization worldwide chart. There were nearly half a million of multidrug-resistant cases. 95 percent of deaths occurred in middle and low-income countries. TB and HIV diseases are the leading killer of people.
According to the UPI, Heiser said, they killed and broke the bacteria then purified the biobeads. They are complete natural and known to be biodegradable. And also they saw evidence of cell-mediated immunity with the potential to be protective against TB. The current TB vaccine was created in 1921 and can cause the disease in people with compromised immune systems. The new tuberculosis vaccine is expected to be much better than the current one, along with additional study and lab tests, there are high hopes in this new developed vaccine.
